Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer

Gynecologic Oncology

Volumn 68, Issue 2, 1998, Pages 166-168

  Brown, John V ^a   Rettenmaier, Mark A ^a   Dillman, Robert A ^a   Birk, Connie L ^a   Culkin, Kathleen ^a   Micha, John Paul ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; LORAZEPAM; ONDANSETRON; PACLITAXEL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032007151     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4916     Document Type: Article

References (15)

1. Ozols, R, F, Rubin, S, C, Thomas, G, M, Robboy, S, J, Epithelial Ovarian Cancer, Principles and Practice of Gynecologic Oncology, Philadelphia, PA, 1997.
2. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
3. Eisenhauer E A, ten Bokkel Huinink W W, Swenerton K D, Gianni L, Mylews J, van der Burg M EL, Kerr I, Vermorken J B, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol. 12:1994;2654-2666.
4. Alberts D S, Green S, Hannigan E V, O'Toole R, Stock-Novack D, Anderson P, Surwit E A, Malvlya V K, Nahhas W A, Jolles C J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 10:1992;707-717.
5. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, Maclean G, Kirk M E, Canetta R, Koski B, Shelly W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cycleophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada clinical Trials Group. J Clin Oncol. 10:1992;718-726.
6. Calvert A H, Newell D R, Gunbrell L A, O'Reilly S, Burnell M, Boxall Fe, Siddik Z H, Judson I R, Gore M E, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1989;1748-1756.
7. Jelliffe R W. Creatinine clearance: Bedside estimate. Ann Intern Med. 79:1973;605.
8. 1995.
9. Neijt J P, Hansen M, Hansen S W, Sorensen P G, Sessa C, Witteveen P O, Engelholm S A, Stigaard L, Roer O, Lund B. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol. 16:1997;352a.
10. Bookman M A, McGuire W P, Kilpatrick D, Keenan E, Hogan M, Johnson S W, O'Dwyer P, Rowinsky E, Gallion H H, Ozols R F. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol. 14:1996;1895-1902.
11. Jakobsen A, Bertelsen K, Andersen J E, Havsteen H, Jakobsen P, Moeller K A, Nielsen K, Sandberg E, Stroeyer I. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study. J Clin Oncol. 15:1997;193-198.
12. Citardi M, Rowinsky E K, Schaefer K I. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. Proc Am Assoc Cancer Res. 31:1990;2431.
13. Rowinsky E K, Gilbert M R, McGuire W P, Noe D A, Grochow L B, Forastiere A A, Ettinger D S, Lubejko B G, Clark B, Sartorius S E, Cornblath D R, Hendricks C B, Donehower R C. Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol. 9:1991;1692-1703.
14. Ten Bokkel Huinink W, Veenjof C, Huizing M, Rodenhuis S, Helmerhorst T, Dubbelman R, Dalesio O, Beijnen J, Winograd B. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol. 24:1997;S2-31-S2-33.
15. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol. 62:1996;166-168.